Editorial Board About Us

Patrick Lefebvre

All articles from this author are listed below.

Volume 23, Number 2 Prostate Cancer

Real-World Comparison of Deep Prostate-Specific Antigen Response in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide or Enzalutamide

Benjamin H. Lowentritt Ibrahim Khilfeh Dominic Pilon Shawn Du Carmine Rossi Frederic Kinkead Lilian Diaz Jill Korsiak Patrick Lefebvre Gordon A Brown

Deep prostate-specific antigen reduction of at least 90% (PSA90 response) after androgen receptor pathway inhibitor initiation to treat metastatic castration-sensitive prostate cancer (mCSPC) is associated with longer survival. This real-world study evaluated the proportion of androgen receptor pathway inhibitor–naive patients with mCSPC who achieved PSA90 response 6 months after initiating apalutamide or enzalutamide.

Prostatic neoplasms Prostate-specific antigen (PSA)Prostate-specific antigen Prostate-specific antigens Castration Androgen receptor Androgen receptor antagonists treatment effectiveness